Kisspeptin-10
Evidence: B-/C+ — Meaningful Human EvidenceHormone / Fertility
Key facts
- Research areaHormone / Fertility
- Research statusinvestigational
- Study records32 human
- Last updated2026-07-26
Evidence Snapshot
Regulatory Context
Investigational; no FDA-approved marketed Kisspeptin-10 medicine was identified. Human physiology studies exist, but they do not establish routine therapeutic use.
In Plain English
A quick, research-focused overview. It does not replace, and cannot outrank, the detailed evidence below.
What is it?
Kisspeptin-10 is a short active kisspeptin fragment studied as a probe and potential modulator of the human reproductive axis. Direct human administration studies are small and indication-specific.
Why are researchers interested in it?
Researchers use KP-10 to study GnRH neuronal function, gonadotropin secretion, sexual dimorphism, and selected reproductive-endocrine disorders.
What is it being studied for?
- LH pulsatility and testosterone response (male hypogonadism)Human Studies & Clinical Data
- Sexual desire and brain processing (hypoactive sexual desire disorder)Human Studies & Clinical Data
- Kisspeptin receptor / reproductive-axis mechanismAnimal / Cell / Preclinical Data
What does the evidence look like?
Evidence grade C. Human, preclinical, regulatory, review, and anecdotal evidence must remain separated.
Biggest things to know
Kisspeptin-10 must remain distinct from kisspeptin-54. Results and dosing from KP-54 studies cannot be automatically assigned to KP-10.
What don't we know yet?
Human studies of kisspeptin-10 are small, short, and measure acute hormone responses (LH pulsatility, testosterone) rather than long-term treatment outcomes — repeated or prolonged stimulation may behave differently than the single-dose or short studies available. It is not an FDA-approved drug, and FDA evaluated it for the compounding Bulks List and proposed against inclusion while separately flagging limited safety information and possible immunogenicity concerns for compounded use. Findings from kisspeptin-10 must not be assumed to apply to kisspeptin-54 or other KISS1-derived fragments, which are chemically distinct.
Research status
Reviewed August 25, 2026
Research Takeaway
Kisspeptin-10 is a 10-amino-acid KISS1-derived peptide that activates the kisspeptin receptor and stimulates hypothalamic GnRH-dependent reproductive-axis signaling; it is distinct from kisspeptin-54 and other KISS1-derived fragments.
Evidence boundary: Biological activity shared across kisspeptin fragments does not establish pharmacokinetic or therapeutic interchangeability.
See all 6 evidence claims →Quick Summary
Kisspeptin-10 is a short active kisspeptin fragment studied as a probe and potential modulator of the human reproductive axis. Direct human administration studies are small and indication-specific.
Mechanism & Research Overview
Kisspeptin-10 is the ten-amino-acid C-terminal active fragment of kisspeptin. It activates the KISS1 receptor and can stimulate hypothalamic GnRH signaling, which in turn affects pituitary LH and FSH release.
Mechanism pathway
Relationship-support labels describe the type and directness of the research available, not proof of safety or effectiveness. Indirectly supported, inferred and uncertain relationships are not equivalent to directly supported ones.
- CompoundKisspeptin-10
- Directly supported (Directly supported relationship)Biological targetKisspeptin receptorReceptor
- Supported indirectly (Indirectly supported relationship)Signal / mechanism stepHypothalamic GnRH releaseKisspeptin receptor activation stimulates GnRH-dependent signaling.
- Leads toPathwayReproductive & Endocrine Signaling
- Contributes to
- Biological processPituitary LH/FSH release
Relationship support in this pathway
- Directly supported
- Supported indirectly
Thin grey links (“Leads to”, “Contributes to”) show structure only and carry no support rating.
Relationship details
- Kisspeptin-10 → Kisspeptin receptor — Directly supportedActivates the kisspeptin receptor, stimulating hypothalamic GnRH-dependent signaling.
- Hypothalamic GnRH release — Supported indirectlySources: b07-kisspeptin-10-01-kisspeptin-10-is-a-potent-stimulator-of-lh-and-incre
- Pituitary LH/FSH release — contributes to the pathway (structural link, no support rating)Sources: b07-kisspeptin-10-01-kisspeptin-10-is-a-potent-stimulator-of-lh-and-incre
A biological process is not the same as a proven health or treatment outcome.
Relevant tissue/system context: Hypothalamic-pituitary-gonadal axis
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Kisspeptin-10 is a 10-amino-acid KISS1-derived peptide that activates the kisspeptin receptor and stimulates hypothalamic GnRH-dependent reproductive-axis signaling; it is distinct from kisspeptin-54 and other KISS1-derived fragments.
Does not establish
Evidence boundary: Biological activity shared across kisspeptin fragments does not establish pharmacokinetic or therapeutic interchangeability.
Sources: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men
Supported
Human studies show that kisspeptin-10 can acutely increase LH pulsatility and testosterone in men, including a small proof-of-concept study in men with type 2 diabetes and central hypogonadism.
Does not establish
Evidence boundary: Acute endocrine responses do not establish long-term treatment efficacy, fertility benefit, or a validated testosterone-replacement alternative.
Sources: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men; Kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and low testosterone
Supported
Kisspeptin-10 is not an FDA-approved drug; FDA evaluated it for the 503A Bulks List and proposed against inclusion, while separately identifying significant safety and characterization uncertainties for compounded use.
Does not establish
Evidence boundary: Compounding-list review is distinct from approval of a drug as safe and effective.
Sources: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Supported
FDA states that safety information for proposed compounded routes of Kisspeptin-10 is absent or limited and identifies potential immunogenicity and peptide-impurity concerns.
Does not establish
Evidence boundary: Limited safety information is not evidence that serious toxicity is present, but it also must not be represented as evidence of safety.
Sources: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Supported
Existing human endocrine and neurobehavioral studies do not establish Kisspeptin-10 as an approved treatment for male hypogonadism, infertility, sexual dysfunction, or testosterone enhancement.
Does not establish
Evidence boundary: Physiologic proof of mechanism is not equivalent to demonstrated long-term clinical benefit.
Sources: Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men; Kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and low testosterone
Supported
Compounded or grey-market Kisspeptin-10 products are unapproved and cannot be presumed equivalent to research-grade material used in clinical studies; only named-study dosing may be displayed as Study/Trial Dosing.
Does not establish
Evidence boundary: This does not provide or endorse a consumer dosing protocol.
Sources: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Human studies are generally small and short, so uncommon or long-term risks are not well characterized.Safety Consideration
Repeated or prolonged stimulation may produce different endocrine effects than a single bolus.Safety Consideration
Kisspeptin-54 evidence must not be reassigned to Kisspeptin-10.
Research Areas Being Studied
Research areas discussed on this page reflect the Hormone / Fertility category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
Show findings from 2 human studies
- Kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and low testosterone (2013):
- Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men (2011):
Study Tables by Evidence Type
3 study records
Human Studies & Clinical Data(2)
Kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and low testosterone
2013PMID 23153270
- Population / Model
- Hypotestosteronemic men with type 2 diabetes
- Dose / Duration / Finding
KP-10 increased LH pulse frequency, LH secretion, and testosterone in this proof-of-concept study.
Safety note
Small, short-term study; it does not establish chronic therapy or clinical outcomes.
Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men
2011PMID 21632807 · DOI 10.1210/jc.2011-0089
- Population / Model
- Healthy adult men in dose-response bolus and infusion studies
- Dose / Duration / Finding
KP-10 produced rapid dose-dependent LH responses; continuous infusion increased LH pulse frequency and size and increased testosterone.
- Study/Trial Dosing:
- Intravenous boluses from 0.01 to 3.0 micrograms/kg and a continuous infusion design were studied.
- Duration:
- Acute bolus and infusion up to approximately 22.5 hours.
Safety note
Short controlled physiology study; not designed to establish long-term therapeutic safety.
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries(1)
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
2026- Population / Model
- Dose / Duration / Finding
FDA states that compounded Kisspeptin-10 may pose immunogenicity and peptide-characterization risks and that safety information for proposed routes is absent or limited. The same FDA page separately flags Epitalon and emideltide/DSIP for substantial safety-information gaps in compounded use.
Show full finding
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-07-26.
Follow research updates for Kisspeptin-10
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.